October 9, 2014 : Episode 1

2014 ESMO Congress Highlights

Video

Related Videos
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Erin K. Crane, MD, MPH
Núria Agustí Garcia, MD
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Gabriella Smith, MD
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Debra L. Richardson, MD, FACS, FACOG
Premal Thaker, MD, MS
Debra L. Richardson, MD, FACS, FACOG
Related Content
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, consultant medical oncologist, Guy’s and St Thomas’ NHS Foundation Trust, NIHR Guy’s Clinical Research Facility

First-Line Rucaparib Maintenance Provides Long-Term Benefits in Newly Diagnosed Ovarian Cancer

April 14th 2024
Article
Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

April 20th 2023
Podcast
Maurie Markman, MD

The Critical Nature of Decision-Making in the Development of Phase 3 Clinical Trials

April 12th 2024
Article
Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

July 18th 2022
Podcast
Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

April 8th 2024
Article
C. Michel Zwaan, MD, PhD, of Erasmus MC Rotterdam and the Princess Máxima Center

Revumenib Demonstrates Activity in Pediatric Patients With KMT2A+ Acute Leukemia

April 4th 2024
Article